secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2026-09-15T11:06:34+00:00
Accession:  0001835268-26-000034
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rademikibart Phase 2 asthma: FEV1 up 130mL (p=0.023); treatment failure down 66% (p=0.153)
--------------------------------------------------------------------------------

- FEV1 at Day 7 improved 250 mL vs 120 mL placebo (130 mL delta, p=0.023), a statistically significant key secondary.
- Treatment failure within 28 days reduced ~66% vs placebo but missed significance (p=0.153) due to lower-than-expected event rate.
- ED/unscheduled visits for worsening asthma cut 50% vs placebo; safety comparable, 1 SAE rademikibart vs 3 placebo.
- 160 patients (79 rademikibart 600mg, 81 placebo); FDA Phase 3 alignment planned; COPD (CBP-201-207) data due later this month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000034/0001835268-26-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000034/cntb-20260915.htm
  HTML page:      https://secwatch.observer/filing/0001835268-26-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer